Open AccessTargeted therapy: resistance and re‐sensitization
Author(s) -
Chen DaoHong,
Zhang XiaoShi
Publication year - 2015
Publication title -
cancer communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.119
H-Index - 53
ISSN - 2523-3548
DOI - 10.1186/s40880-015-0047-1
Subject(s) - targeted therapy , medicine , cancer therapy , drug resistance , adverse effect , cancer , clinical trial , drug , computational biology , bioinformatics , pharmacology , biology , microbiology and biotechnology
Abstract The last two decades have witnessed a paradigm shift from cytotoxic drugs to targeted therapy in medical oncology and pharmaceutical innovation. Inspired by breakthroughs in molecular and cellular biology, a number of novel synthesized chemical compounds and recombinant antibodies have been developed to selectively target oncogenic signaling pathways in a broad array of tumor types. Although targeted therapeutic agents show impressive clinical efficacy and minimized adverse effects compared with traditional treatments, the challenging drug‐resistant issue has also emerged to limit their benefits to cancer patients. In this regard, we aim to improve targeted therapy by presenting a systematic framework regarding the drug resistance mechanisms and alternative approaches to re‐sensitize cancer cells/tissues therapeutically.